[{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CTI Clinical Trial and Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ CTI Clinical Trial and Consulting","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ CTI Clinical Trial and Consulting"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Quotient Sciences"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Nucleus Network","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Nucleus Network","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Nucleus Network"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Nephrology","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Terevalefim","moa":"Hepatocyte growth factor receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase III","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Vifor Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Angion Biomedica \/ Vifor Pharma"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002","moa":"KRAS","graph1":"Oncology","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Angion Biomedica","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Angion Biomedica"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANG-3070","moa":"ROR1 receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Angion Biomedica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angion Biomedica \/ Undisclosed"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Quotient Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"14-C ANG-3777","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Angion Biomedica \/ Quotient Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Angion Biomedica \/ Quotient Sciences"},{"orgOrder":0,"company":"Angion Biomedica","sponsor":"Elicio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Merger","leadProduct":"ELI-002 7P","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Angion Biomedica","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angion Biomedica \/ Elicio Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Angion Biomedica \/ Elicio Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by Angion Biomedica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The combined company will focus on the advancement of its clinical development program, ELI-002, a therapeutic cancer vaccine designed with Elicio’s proprietary lymph node-targeting AMP technology, being evaluated in patients with mKRAS-driven solid tu...

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          June 01, 2023

                          Lead Product(s) : ELI-002 7P

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Elicio Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The combined company will focus on advancing Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology to develop immunotherapies, with a focus on ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors.

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 17, 2023

                          Lead Product(s) : ELI-002

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Elicio Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Merger

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ANG-3070, an oral tyrosine kinase inhibitor (TKI), in patients with primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 29, 2022

                          Lead Product(s) : ANG-3070

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ANG-3070 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Idiopathic Pulmonary Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 24, 2022

                          Lead Product(s) : ANG-3070

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ANG-3070 is an oral tyrosine kinase inhibitor targeting platelet-derived growth factor receptor alpha and beta and Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2), tyrosine kinase receptors linked to the development of fibrosis in the kidneys and lung...

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 16, 2022

                          Lead Product(s) : ANG-3070

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The results from the Phase 2 GUARD trial of Angion’s ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 09, 2021

                          Lead Product(s) : Terevalefim

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : CSL Vifor

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : ANG-3777 is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF), trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC).

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 09, 2021

                          Lead Product(s) : Terevalefim

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The presentation describes preclinical data from a study of ANG-3070 in a mouse unilateral ureteral obstruction (UUO) model, a well-established model for obstructive renal disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 05, 2021

                          Lead Product(s) : ANG-3070

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The overall safety profile of ANG-3777 in this trial was consistent with the overall experience in its clinical development program and consistent with the published literature in this patient population.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 26, 2021

                          Lead Product(s) : Terevalefim

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Phase III

                          Sponsor : CSL Vifor

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : The Phase 1 study was a randomized, double-blind, and placebo-controlled study in healthy volunteers conducted in Australia to assess the safety, tolerability, pharmacokinetics, and food effect of ANG-3070 dosed orally.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 03, 2021

                          Lead Product(s) : ANG-3070

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank